Investor Relations

Established in 2020, Genflow Biosciences Ltd is a UK-based biotechnology company, with R&D facilities in Belgium, developing and researching potential novel therapeutics that halt or slow the ageing process enabling society to live longer, healthier lives. Genflow Biosciences lead compound is GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow Biosciences will commence a clinical trial in 2025 to study the potential benefit of GF-1002 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) for which there are few or no-approved therapies. By treating ageing as a risk factor to disease, Genflow Biosciences aims to reduce the financial, emotional, and social costs of an ageing population.